TechCrunch Startup News Orakl Oncology combines data and biology to bring new drugs to cancer patients
Dec 4, 2024
The podcast dives into the alarming rise of cancer among younger adults and the staggering failure rates of new drug compounds in clinical trials. Fanny Jaulin discusses the need for innovative trial designs to improve outcomes. It highlights how a startup is leveraging AI to revolutionize drug discovery by tailoring treatments to individual patient profiles, particularly for colorectal and pancreatic cancers. Their recent funding successes signal a promising advance in the realm of precision medicine.
AI Snips
Chapters
Transcript
Episode notes
Clinical Trial Design Flawed
- Cancer incidence is rising, especially among younger adults, but most new drug compounds fail clinical trials.
- Fanny JoLynn believes the issue lies in clinical trial design, not necessarily drug efficacy.
Orakl Oncology's Hybrid Approach
- Orakl Oncology combines AI with biological approaches, similar to Tempus.
- This hybrid approach uses data to address tumor uniqueness and biological methods to manage cancer's complexity.
Data and Biology Combined
- Orakl Oncology uses a hybrid approach combining data analysis with biological research.
- They utilize organoids, miniaturized organs, for trials and collect around 40 variables per patient.